Novo Nordisk A/S (NYSE:NVO) Trading Up 0.4%

Novo Nordisk A/S (NYSE:NVO) rose 0.4% during trading on Wednesday . The company traded as high as $129.24 and last traded at $128.82. Approximately 1,597,565 shares traded hands during trading, a decline of 66% from the average daily volume of 4,760,968 shares. The stock had previously closed at $128.31.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. BMO Capital Markets began coverage on shares of Novo Nordisk A/S in a research note on Friday, April 12th. They set an “outperform” rating and a $163.00 price objective on the stock. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price objective for the company. UBS Group started coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 16th. They issued a “neutral” rating for the company. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $133.60.

Novo Nordisk A/S Stock Down 0.8 %

The company has a market capitalization of $552.33 billion, a price-to-earnings ratio of 45.50, a P/E/G ratio of 2.16 and a beta of 0.43. The company has a quick ratio of 0.64, a current ratio of 0.82 and a debt-to-equity ratio of 0.19. The firm has a 50 day moving average price of $127.21 and a two-hundred day moving average price of $112.77.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.66 by $0.05. The company had revenue of $9.51 billion for the quarter, compared to the consensus estimate of $9.14 billion. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. As a group, sell-side analysts expect that Novo Nordisk A/S will post 3.32 earnings per share for the current year.

Institutional Trading of Novo Nordisk A/S

Several institutional investors have recently added to or reduced their stakes in the stock. Pacific Center for Financial Services lifted its position in shares of Novo Nordisk A/S by 100.0% during the third quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock worth $25,000 after purchasing an additional 135 shares during the last quarter. First PREMIER Bank bought a new stake in shares of Novo Nordisk A/S in the 1st quarter valued at approximately $25,000. Bell Investment Advisors Inc raised its position in shares of Novo Nordisk A/S by 79.9% during the 3rd quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock valued at $26,000 after acquiring an additional 127 shares in the last quarter. CNB Bank acquired a new position in Novo Nordisk A/S in the fourth quarter worth $26,000. Finally, Dixon Mitchell Investment Counsel Inc. bought a new stake in Novo Nordisk A/S during the first quarter valued at $26,000. 11.54% of the stock is owned by institutional investors and hedge funds.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.